Fig. 7.

C44-Fc administrations reduce serum lipid levels for 6 weeks. a Schematic illustration of experimental design to assess the therapeutic effects of C44-Fc in NAFLD mice after multiple administrations. NAFLD model in C57BL/6 mice were induced by HF/HCCD-fed for 8 weeks and then treated with 25 mg/kg of isotype control Ab, 25 mg/kg of C44-Fc, or 25 mg/kg of evinacumab weekly. Serum TG (b), TC (c) and LDL-C (d) levels were weekly tested 4 days after antibody administrations (n = 6). Plasma lipoproteins of cholesterol (e) were separated by HPLC and measured in each fraction. § and * respectively represent the Student’s t-test of 25 mg/kg C44-Fc and 25 mg/kg evinacumab treatment compared with control Ab